M.D. Ph.D. Craig B. Granowitz - 28 Feb 2024 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Role
SVP, Chief Medical Officer
Signature
/s/ Craig B. Granowitz, M.D., Ph.D.
Issuer symbol
LXRX
Transactions as of
28 Feb 2024
Net transactions value
-$81,914
Form type
4
Filing time
29 Feb 2024, 16:28:56 UTC
Previous filing
12 Feb 2024
Next filing
18 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXRX Common Stock Options Exercise +27,916 +184% 43,101 28 Feb 2024 Direct F1
transaction LXRX Common Stock Options Exercise +35,790 +83% 78,891 28 Feb 2024 Direct F1
transaction LXRX Common Stock Tax liability $81,914 -31,265 -40% $2.62 47,626 28 Feb 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LXRX Restricted Stock Units Options Exercise -27,916 -50% 27,917 28 Feb 2024 Common Stock 27,916 Direct F1, F3
transaction LXRX Restricted Stock Units Options Exercise -35,790 -33% 71,580 28 Feb 2024 Common Stock 35,790 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock.
F2 Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
F3 Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.